热门资讯> 正文

Abivax SA将ADS产品价格上调8亿美元

2026-07-01 20:56

Abivax SA (ABVX) priced an upsized public offering of 6.4M ADSs at $125/ADS, raising ~$800M in gross proceeds.
The offering size was increased from the previously announced $600M.
The company granted underwriters a 15% option to purchase up to 960,000 additional ADSs, potentially increasing gross proceeds to about $920M.
The offering is expected to close on July 6, 2026.
Abivax plans to use the proceeds to support the commercialization of obefazimod, fund clinical development, and for general corporate purposes.

More on Abivax

ABIVAX Société Anonyme (ABVX) Discusses ABTECT Maintenance Part 2 Results and Updated Obefazimod Safety and Efficacy Data in Ulcerative Colitis - Slideshow
Abivax: Latest Obefazimod Data Eases Safety Fears, Brings M&A Back Into Play
ABIVAX Société Anonyme (ABVX) Discusses ABTECT Maintenance Part 2 Results and Updated Obefazimod Safety and Efficacy Data in Ulcerative Colitis Transcript
Abivax launches $600M underwritten public offering
Abivax stock jumps on positive Phase 3 ulcerative colitis data

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。